Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. - Patel K; Vose JM; Nasta SD; Brown JR; Maddocks KJ; Woyach JA; Shah NN; Fakhri B; Tessoulin B; Ma S; Jagadeesh D; Lech-Maranda E; et al. (Blood advances, 2026)